[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362040-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362040-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-upr-related-long-noncoding-rnas-in-development-of-endocrine-resistance-in-breast-cancer","The role of UPR-related long noncoding RNAs in development of endocrine resistance in breast cancer","","Breast cancer patients expressing estrogen receptor α (ER) typically receive endocrine therapy first, yet up to 40% develop endocrine resistance over time. Resistance is linked to aberrant ER pathway reactivation driven by genetic and epigenetic alterations and involving endoplasmic reticulum (EnR) stress and the unfolded protein response (UPR). This review summarizes long noncoding RNAs (lncRNAs) that connect UPR and ER signaling and explores targeting these lncRNAs as potential strategies to improve outcomes in endocrine-resistant, ER-positive breast cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-upr-related-long-noncoding-rnas-in-development-of-endocrine-resistance-in-breast-cancer/362040/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-upr-related-long-noncoding-rnas-in-development-of-endocrine-resistance-in-breast-cancer/362040.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do ER-positive breast cancer patients develop endocrine resistance over time?","Question",{"text":63,"@type":64},"Most initially respond to endocrine therapy, but up to 40% later develop resistance characterized by clinical relapses and reactivation of ER signaling driven by genetic and epigenetic changes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does endoplasmic reticulum stress and UPR play in this process?",{"text":68,"@type":64},"UPR is a cellular stress response initiated at the endoplasmic reticulum when unfolded or misfolded proteins accumulate, and it is described as crucial in determining cell fate during resistance development.",{"name":70,"@type":61,"acceptedAnswer":71},"How do long noncoding RNAs relate to endocrine resistance and UPR signaling?",{"text":72,"@type":64},"The review highlights noncoding RNAs involved in crosstalk between UPR and ER signaling, emphasizing lncRNAs that participate in both endocrine resistance and UPR pathways.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362040,1790192646,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10.1002/ijc.70067  \nREVIE W  \nThe role of UPR-related long noncoding RNAs in development of endocrine resistance in breast cancer  \nWen Liu | Sahil Gupta | Sanjeev Gupta   \nDiscipline of Pathology, Cancer Progression and Treatment Research Group, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland  \nCorrespondence  \nSanjeev Gupta, Discipline of Pathology, Cancer Progression and Treatment Research Group, Lambe Institute for Translational Research, School of Medicine, University of Galway, 3rd Floor, Galway, Ireland.  \nEmail: [sanjeev.gupta@universityofgalway.ie](sanjeev.gupta@universityofgalway.ie)  \nFunding information  \nChina Scholarship Council, Grant/Award Number: 202106370068  \nAbstract  \nBreast cancer patients who express estrogen receptor α (ER) typically receive endocrine therapy as a first-line treatment. Most ER-positive breast cancer patients initially respond to endocrine therapy, but up to 40% of patients develop resistance over time, and the main mechanism is aberrant activation of ER signaling pathways. Recent research has shown that cancer's uncontrolled proliferative capacity and a hostile microenvironment can induce endoplasmic reticulum (EnR) stress and trigger unfolded protein response (UPR), which plays a crucial role in determining cell fate. Furthermore, increasing evidence suggests that noncoding ribonucleic acids (RNAs), which are involved during the crosstalk between the UPR and ER signaling pathways, play an essential role in endocrine resistance. In this review, we provide an overview of long noncoding RNA (lncRNA) that is involved both in endocrine resistance and UPR. We provide new insights into potential treatment strategies to overcome endocrine resistance in ER-positive breast cancer patients by targeting the lncRNA that plays key roles in endocrine resistance and UPR signaling. Finally, we discuss the current state and future directions for targeting lncRNAs to improve clinical outcomes in endocrine-resistant breast cancer patients.  \nKEYWOR DS  \nbreast cancer, endocrine resistance, long noncoding RNA, unfolded protein response  \nAbbreviations: AP-1, activator protein 1; ASO, antisense oligonucleotide; ATF4, activating transcription factor 4; BCAR4, breast cancer anti-estrogen resistance 4; CHOP, C/EBP homologous protein; CYTOR, cytoskeleton regulator RNA; DC, dendritic cell; DNMT3B, DNA methyltransferase 3 beta; EGF, epidermal growth factor; EnR, endoplasmic reticulum; ER, estrogen receptor α; Eleanors, ESR1 locus enhancing and activating noncoding RNAs; EZH2, enhancer of zeste homolog 2; FAM83H-AS1, FAM83H antisense RNA 1; FOXO3, Forkhead box class O protein 3; GADD34, growth arrest and DNA damage-inducible 34; GAS5, growth arrest-specific transcript 5; HMGA1, high mobility group AT-hook1; HOTAIR, HOX antisense intergenic RNA; HOTAIRM1, HOX antisense intergenic RNA myeloid 1; IGF2, insulin-like growth factor 2; IRE1α, inositol requiring enzyme1α; LINP1, LncRNA in nonhomologous end joining pathway 1; JNK, c-Jun N-terminal kinase; LDHA, lactate dehydrogenase A; lncRNAs, long noncoding RNAs; MEG3, maternally expressed 3; NF-κB, nuclear factor κB; OCT4, octamer-binding transcription factor 4; PDE4D, phosphodiesterase 4D; PERK, protein kinase RNA-like endoplasmic reticulum kinase; RNA, ribonucleic acids; ROR, regulator of reprogramming; SNHG6, small nucleolar RNA host gene 6; SOX2, SRY-Box transcription factor 2; SOX2OT, SOX2 overlapping transcript; SP-1, stimulating protein-1; TRAF2, tumor necrosis factor receptor-associated factor 2; UBA6, ubiquitin like modifier activating enzyme 6; UBA6-AS1, UBA6 antisense RNA 1; UCA1, urothelial carcinoma associated 1; XBP1, X-box binding protein 1; XBP1u, X-box binding protein 1mRNA.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is ","cbCaivOZLjvM6bA0","https://ap.wps.com/l/cbCaivOZLjvM6bA0","pdf",2022963,13,"English","# Introduction\n## Breast cancer and endocrine therapy\n## Endoplasmic reticulum stress and UPR\n# Long noncoding RNAs and endocrine resistance\n## lncRNAs linking UPR and ER signaling\n# Therapeutic implications\n## Targeting lncRNAs for improved outcomes","[{\"question\":\"Why do ER-positive breast cancer patients develop endocrine resistance over time?\",\"answer\":\"Most initially respond to endocrine therapy, but up to 40% later develop resistance characterized by clinical relapses and reactivation of ER signaling driven by genetic and epigenetic changes.\"},{\"question\":\"What role does endoplasmic reticulum stress and UPR play in this process?\",\"answer\":\"UPR is a cellular stress response initiated at the endoplasmic reticulum when unfolded or misfolded proteins accumulate, and it is described as crucial in determining cell fate during resistance development.\"},{\"question\":\"How do long noncoding RNAs relate to endocrine resistance and UPR signaling?\",\"answer\":\"The review highlights noncoding RNAs involved in crosstalk between UPR and ER signaling, emphasizing lncRNAs that participate in both endocrine resistance and UPR pathways.\"}]","The role of UPR-related long noncoding RNAs in development of endocrine resistance in breast cancer | PDF",1790146335,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff1b05f370abfb959d5da2b6fbfd679d.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12decb042f029c1897e18ce33a192bac.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a20baa3e0a058bf57dea4c61059b8b5.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a95a45002b938e61be8116808b7c32d9.webp",980,1287]